S100B and infection: In conclusion, although the MRKAd5 HIV-1 Gag/Pol/Nef vaccine increased the infection risk among vaccine recipients in the Step and Phambili trials [7, 8, 10], these data suggest its potential role as a therapeutic vaccine operating in an HLA-specific manner, with the capacity to benefit individuals expressing disease-susceptible alleles.